These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 34616368)
1. Corrigendum: ACE Gene Variants Rise the Risk of Severe COVID-19 in Patients With Hypertension, Dyslipidemia or Diabetes: A Spanish Pilot Study. Íñiguez M; Pérez-Matute P; Villoslada-Blanco P; Recio-Fernandez E; Ezquerro-Pérez D; Alba J; Ferreira-Laso ML; Oteo JA Front Endocrinol (Lausanne); 2021; 12():771445. PubMed ID: 34616368 [TBL] [Abstract][Full Text] [Related]
2. ACE Gene Variants Rise the Risk of Severe COVID-19 in Patients With Hypertension, Dyslipidemia or Diabetes: A Spanish Pilot Study. Íñiguez M; Pérez-Matute P; Villoslada-Blanco P; Recio-Fernandez E; Ezquerro-Pérez D; Alba J; Ferreira-Laso ML; Oteo JA Front Endocrinol (Lausanne); 2021; 12():688071. PubMed ID: 34489863 [TBL] [Abstract][Full Text] [Related]
3. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166 [TBL] [Abstract][Full Text] [Related]
4. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia]. Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596 [TBL] [Abstract][Full Text] [Related]
5. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia]. Nowakowska A Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609 [TBL] [Abstract][Full Text] [Related]
6. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19. Khera R; Clark C; Lu Y; Guo Y; Ren S; Truax B; Spatz ES; Murugiah K; Lin Z; Omer SB; Vojta D; Krumholz HM J Am Heart Assoc; 2021 Jul; 10(13):e018086. PubMed ID: 33624516 [TBL] [Abstract][Full Text] [Related]
7. Corrigendum: Effectiveness of Remotely Delivered Interventions to Simultaneously Optimize Management of Hypertension, Hyperglycemia and Dyslipidemia in People With Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Fernando ME; Seng L; Drovandi A; Crowley BJ; Golledge J Front Endocrinol (Lausanne); 2022; 13():916377. PubMed ID: 35615715 [TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin system gene polymorphisms, blood pressure, dyslipidemia, and diabetes in Hong Kong Chinese: a significant association of tne ACE insertion/deletion polymorphism with type 2 diabetes. Thomas GN; Tomlinson B; Chan JC; Sanderson JE; Cockram CS; Critchley JA Diabetes Care; 2001 Feb; 24(2):356-61. PubMed ID: 11213892 [TBL] [Abstract][Full Text] [Related]
9. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients. Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528 [TBL] [Abstract][Full Text] [Related]
10. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Kohno M; Yokokawa K; Minami M; Kano H; Yasunari K; Hanehira T; Yoshikawa J Am J Med; 1999 May; 106(5):544-9. PubMed ID: 10335726 [TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes. Bozkurt O; de Boer A; Grobbee DE; Kroon AA; Schiffers P; de Leeuw P; Klungel OH J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):101-8. PubMed ID: 19502258 [TBL] [Abstract][Full Text] [Related]
13. The Angiotensin Converting Enzyme Deletion/Deletion Genotype Is a Risk Factor for Severe COVID-19: Implication and Utility for Patients Admitted to Emergency Department. Annunziata A; Coppola A; Di Spirito V; Cauteruccio R; Marotta A; Micco PD; Fiorentino G Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441050 [No Abstract] [Full Text] [Related]
14. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome. Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356 [TBL] [Abstract][Full Text] [Related]
15. Corrigendum: Diabetes as a risk factor of death in hospitalized COVID-19 patients - an analysis of a National Hospitalization Database from Poland, 2020. Kania M; Koń B; Kamiński K; Hohendorff J; Witek P; Klupa T; Malecki MT Front Endocrinol (Lausanne); 2023; 14():1228521. PubMed ID: 37469983 [TBL] [Abstract][Full Text] [Related]
16. [The effect of the angiotensinogen M235T and the angiotensin-converting enzyme I/D polymorphisms on arterial hypertension and other cardiovascular risk factors]. Pamies Andreu E; Palmero Palmero C; García Lozano R; Stiefel García-Junco P; Miranda Guisado ML; Martín Sanz V; Villar Ortiz J; Núñez Roldán A; Carneado de la Fuente J Med Clin (Barc); 1999 Jul; 113(5):164-8. PubMed ID: 10480138 [TBL] [Abstract][Full Text] [Related]
17. Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients. Verma S; Abbas M; Verma S; Khan FH; Raza ST; Siddiqi Z; Ahmad I; Mahdi F Infect Genet Evol; 2021 Jul; 91():104801. PubMed ID: 33676010 [TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2. Hallaj S; Ghorbani A; Mousavi-Aghdas SA; Mirza-Aghazadeh-Attari M; Sevbitov A; Hashemi V; Hallaj T; Jadidi-Niaragh F Immunol Cell Biol; 2021 Feb; 99(2):192-205. PubMed ID: 32864784 [TBL] [Abstract][Full Text] [Related]
19. Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. Bozkurt O; Verschuren WM; van Wieren-de Wijer BM; Knol MJ; de Boer A; Grobbee DE; Geerlings MI; Heerdink ER; Klungel OH J Hum Hypertens; 2008 Nov; 22(11):774-80. PubMed ID: 18563171 [TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of angiotensin-converting enzyme and angiotensin II receptor type 1 genes in essential hypertension in a Polish population. Dzida G; Sobstyl J; Puzniak A; Golon P; Mosiewicz J; Hanzlik J Med Sci Monit; 2001; 7(6):1236-41. PubMed ID: 11687736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]